- Home
- PLUG vs KROS Comparison
PLUG vs KROS Comparison
Compare PLUG & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | KROS |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 655.9M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLUG | KROS |
|---|---|---|
| Price | $2.10 | $21.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $2.15 | ★ $22.20 |
| AVG Volume (30 Days) | ★ 97.3M | 927.5K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | ★ $676,169,000.00 | $246,718,000.00 |
| Revenue This Year | $13.86 | $6,876.34 |
| Revenue Next Year | $21.99 | N/A |
| P/E Ratio | ★ N/A | $13.58 |
| Revenue Growth | 2.53 | ★ 37798.31 |
| 52 Week Low | $0.69 | $9.12 |
| 52 Week High | $4.58 | $22.55 |
Technical Indicators
Market Signals| Indicator | PLUG | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 64.94 |
| Support Level | $2.09 | $19.76 |
| Resistance Level | $2.49 | $21.76 |
| Average True Range (ATR) | 0.18 | 0.90 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 18.75 | 57.35 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.